Phase II RCT in 200 patients with unresectable HCC: TACE plus camrelizumab and rivoceranib vs TACE alone gave longer median PFS (10.8 vs 3.2 months; HR 0.34). Grade 3+ treatment-related adverse events: 74.5% vs 22.3%.
RCTn = 200
Zhu et al. Transarterial Chemoembolization Combined With Camrelizumab and Rivoceranib for Unresectable Hepatocellular Carcinoma (CHANCE2005/CARES-005): A Randomized Phase II Trial